Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer

Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)

(2020) Neesha C Dhani et al.   CLINICAL CANCER RESEARCH

Second-line lenvatinib in patients with recurrent endometrial cancer

(2020) Ignace Vergote et al.   GYNECOLOGIC ONCOLOGY

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

(2019) Vicky Makker et al.   LANCET ONCOLOGY

Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer

(2019) Isidre Felip et al.   GYNECOLOGIC ONCOLOGY

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

(2019) Rastilav Bahleda et al.   CLINICAL CANCER RESEARCH

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer

(2019) Gaia Giannone et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy

(2019) Charlie Gourley et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of afatinib in a HER2 amplification-positive endometrioid adenocarcinoma patient– a case report

(2019) Li Zhou et al.   OncoTargets and Therapy

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

(2019) Alexandra S. Zimmer et al.   Journal for ImmunoTherapy of Cancer

Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study

(2019) Pamela T. Soliman et al.   CLINICAL CANCER RESEARCH

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway

(2019) Maria M. Rubinstein et al.   CANCER

Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer

(2019) Andrea P. Myers et al.   INTERNATIONAL JOURNAL OF CANCER

Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas

(2019) Alicia León‐Castillo et al.   JOURNAL OF PATHOLOGY

Keratinocyte growth factor protects endometrial cells from oxygen glucose deprivation/re-oxygenation via activating Nrf2 signaling

(2018) Xuting Shi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

(2018) Katherine A. Hoadley et al.   CELL

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

(2018) Johanna C. Bendell et al.   CLINICAL CANCER RESEARCH

A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer

(2018) Carol Aghajanian et al.   GYNECOLOGIC ONCOLOGY

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

(2018) Dejan Juric et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms of receptor tyrosine kinase activation in cancer

(2018) Zhenfang Du et al.   Molecular Cancer

Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late

(2018) Michiel Remmerie et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers

(2018) Z. Ping Lin et al.   Frontiers in Oncology

A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer

(2018) Linda R. Duska et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

(2018) Marthe M. de Jonge et al.   CLINICAL CANCER RESEARCH

Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer

(2018) Fabio Barra et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors

(2017) Jennifer Wheler et al.   ONCOLOGIST

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

(2017) Zev A. Wainberg et al.   Targeted Oncology

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

(2017) Trisha M. Wise-Draper et al.   Targeted Oncology

Epigenetics in endometrial carcinogenesis – part 2: histone modifications, chromatin remodeling and noncoding RNAs

(2017) Carla Bartosch et al.   Epigenomics

A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)

(2016) Vicky Makker et al.   CANCER

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2016) S. O. Dolly et al.   CLINICAL CANCER RESEARCH

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

(2016) Sven Wind et al.   CLINICAL PHARMACOKINETICS

A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer

(2016) Josep María del Campo et al.   GYNECOLOGIC ONCOLOGY

Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models

(2015) Stefanie Schrauwen et al.   GYNECOLOGIC ONCOLOGY

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

(2015) Robert L. Coleman et al.   GYNECOLOGIC ONCOLOGY

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

(2015) Ursula Matulonis et al.   GYNECOLOGIC ONCOLOGY

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

(2015) David Bender et al.   GYNECOLOGIC ONCOLOGY

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

(2015) Johanna C. Bendell et al.   INVESTIGATIONAL NEW DRUGS

Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma

(2015) Amit M. Oza et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma

(2015) Brian M. Slomovitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

(2015) Gottfried E Konecny et al.   LANCET ONCOLOGY

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

(2015) Jennifer J. Wheler et al.   Oncotarget

Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer

(2014) Jiezhong Chen et al.   CURRENT MEDICINAL CHEMISTRY

Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer

(2014) Daliah Tsoref et al.   GYNECOLOGIC ONCOLOGY

A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia

(2014) Vincent Castonguay et al.   GYNECOLOGIC ONCOLOGY

A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study

(2014) Don S. Dizon et al.   GYNECOLOGIC ONCOLOGY

A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study

(2014) Matthew A. Powell et al.   GYNECOLOGIC ONCOLOGY

Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study

(2014) Gini F. Fleming et al.   GYNECOLOGIC ONCOLOGY

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial

(2013) N Colombo et al.   BRITISH JOURNAL OF CANCER

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

(2013) I Ray-Coquard et al.   BRITISH JOURNAL OF CANCER

PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines

(2013) B. Weigelt et al.   CLINICAL CANCER RESEARCH

HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor

(2013) Diana P. English et al.   GYNECOLOGIC ONCOLOGY

Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer

(2013) Rachel A. Goodwin et al.   GYNECOLOGIC ONCOLOGY

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study

(2013) Kimberly K. Leslie et al.   GYNECOLOGIC ONCOLOGY

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

(2012) Kimberly K. Leslie et al.   GYNECOLOGIC ONCOLOGY

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study

(2012) Edwin A. Alvarez et al.   GYNECOLOGIC ONCOLOGY

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

(2012) B. R. Davies et al.   MOLECULAR CANCER THERAPEUTICS

E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion

(2011) Hilary Glen et al.   BMC CANCER

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

(2011) Amit M. Oza et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

(2010) Brian M. Slomovitz et al.   CANCER

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

(2008) Q. S.C. Chu et al.   CLINICAL CANCER RESEARCH

Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148

(2008) Amit M. Oza et al.   JOURNAL OF CLINICAL ONCOLOGY